{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:26:45Z","timestamp":1793921205501,"version":"4.8.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.semarthrit.2026.153079","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:27:49Z","timestamp":1789774069000},"page":"153079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consensus recommendations for optimal trial design and reporting of core domains in urate-lowering therapy trials for gout: A Delphi study"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7846-4080","authenticated-orcid":false,"given":"Ellen","family":"Prendergast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6600-0631","authenticated-orcid":false,"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6445-8526","authenticated-orcid":false,"given":"Martin A","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.153079_bib0001","unstructured":"Beaton DML, Grosskleg S, Shea B, Tugwell P (eds). The OMERACT Handbook version 2.1 [updated March 2021] 2021 Available from: https:\/\/omeracthandbook.org\/."},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153079_bib0002","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153079_bib0003","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153079_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152191","article-title":"Outcome reporting in randomized trials in gout: a systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set","volume":"60","author":"Morillon","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153079_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/acr.25250","article-title":"Uptake of the gout and crystal arthritis network consensus statements for gout nomenclature","volume":"76","author":"Prendergast","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153079_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153079_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3899\/jrheum.170911","article-title":"Variability in the reporting of serum urate and flares in gout clinical trials: need for minimum reporting requirements","volume":"45","author":"Stamp","year":"2018","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153079_bib0008","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.110272","article-title":"Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities","volume":"38","author":"Dalbeth","year":"2011","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153079_bib0009","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/annrheumdis-2014-205671","article-title":"Development of a patient-reported outcome measure of tophus burden: the tophus impact questionnaire (TIQ-20)","volume":"74","author":"Aati","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153079_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40271-016-0198-4","article-title":"Successful stepwise development of patient research partnership: 14 years\u2019 Experience of actions and consequences in outcome measures in rheumatology (OMERACT)","volume":"10","author":"de Wit","year":"2017","journal-title":"Patient - Patient-Centered Outcomes Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153079_bib0011","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-014-0492-x","article-title":"The Gouty Tophus: a review","volume":"17","author":"Chhana","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153079_bib0012","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.153079_bib0013","series-title":"Guideline on clinical investigation of medicinal products for the treatment of gout","year":"2019"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:50:25Z","timestamp":1793919025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":13,"alternative-id":["S0049017226001691"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153079","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations for optimal trial design and reporting of core domains in urate-lowering therapy trials for gout: A Delphi study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153079"}}